Investment Rating - The investment rating for the company is "Buy" (maintained) [7] Core Views - The company's performance in 2024 was impacted by impairment and expense costs, but long-term growth prospects remain positive [7][14] - In 2024, the company achieved operating revenue of 182.07 billion yuan, a year-on-year increase of 3.8%, while net profit attributable to shareholders was 13.03 billion yuan, a year-on-year decrease of 22.5% [4][13] - The company is expected to see revenue growth in the coming years, with projected revenues of 217.2 billion yuan in 2025 and 251.3 billion yuan in 2026, reflecting year-on-year growth rates of 19% and 16% respectively [17] Summary by Sections Financial Performance - In Q4 2024, the company reported operating revenue of 34.46 billion yuan, a year-on-year decrease of 19.5% and a quarter-on-quarter decrease of 31.8% [4][13] - The decline in net profit for Q4 2024 was significant, with a year-on-year drop of 52.8% [4][13] - The company’s main products saw sales volume and revenue growth, but overall gross profit remained stable due to market price fluctuations and raw material costs [14] Market Conditions - The MDI market showed overall improvement in 2024, with average prices for MDI increasing by 9% year-on-year, while TDI prices declined by 20% [15] - Strong export demand and low overseas operating rates contributed to the improved MDI market conditions in Q4 2024 [15] Project Development - The company has successfully launched new projects, including a 200,000-ton POE project and a 48,000-ton citral facility, with further expansions planned [16] - The ongoing construction of the second phase of the POE project is expected to be completed by the end of 2025, which will significantly increase the company's production capacity [16] Earnings Forecast and Valuation - The company’s earnings per share (EPS) are projected to be 4.15 yuan in 2024, with a compound annual growth rate (CAGR) of 5% over the next three years [17] - The company maintains a strong competitive position in the MDI sector and is transitioning towards a more diversified chemical company [17]

Investment Rating - The investment rating for the company is "Buy" (maintained) [6] Core Views - The company's sales performance remains stable, but impairment provisions have negatively impacted its earnings. The company reported a year-on-year increase in revenue but a decline in net profit due to the overall turbulence in the real estate market [6][7] - The company has adjusted its profit forecasts for 2024-2026, expecting net profits of 40.4 billion, 59.7 billion, and 64.7 billion respectively, down from previous estimates of 50.9 billion, 70.0 billion, and 74.0 billion. The current stock price corresponds to a PE ratio of 22.0, 14.9, and 13.8 for the respective years [6][10] - The company continues to focus on acquiring land in core cities, maintaining a strong market position with ample saleable inventory and smooth financing channels, which is expected to enhance its market share in the future [6][8] Financial Performance Summary - In 2024, the company achieved total revenue of 1789.48 billion, a year-on-year increase of 2.25%. However, operating profit decreased by 36.54% to 90.00 billion, and net profit attributable to shareholders fell by 36.09% to 40.4 billion [7][10] - The net cash flow from operating activities was 319.64 billion, a year-on-year increase of 1.69%. By the end of 2024, the company's cash balance was 1003.51 billion, up 120.62 billion or 13.66% year-on-year [8] - The company has made sufficient impairment provisions totaling 59.4 billion, which impacted net profit by 43.4 billion. This includes provisions for credit losses, inventory write-downs, and goodwill impairment [9][10] Financial Forecasts - The company forecasts revenue growth of 5.4% in 2025 and 3.5% in 2026, with expected net profits of 5.97 billion and 6.47 billion respectively [10][16] - The projected EPS for 2024, 2025, and 2026 is 0.45, 0.66, and 0.71 respectively, with a corresponding PE ratio of 22.0, 14.9, and 13.8 [10][16]

深圳市华星光电半导体显示技术有限公司 已审财务报表 2022年度、2023年度及截至2024年10月31日止 10个月期间 深圳市华星光电半导体显示技术有限公司 目 录 | | | 页 次 | | | --- | --- | --- | --- | | 一、 | 审计报告 | 1 - | 3 | | 二、 | 已审财务报表 | | | | | 资产负债表 | 4 | - 5 | | | 利润表 | | 6 | | | 所有者权益变动表 | 7 | - 8 | | | 现金流量表 | 9 - | 10 | | | 财务报表附注 | 11 - | 85 | 审计报告 安永华明（2025）审字第80014905_H01号 深圳市华星光电半导体显示技术有限公司 深圳市华星光电半导体显示技术有限公司董事会： 一、审计意见 我们审计了深圳市华星光电半导体显示技术有限公司的财务报表，包括2022年12 月31日、2023年12月31日及2024年10月31日的资产负债表，2022年度、2023年度及 截至2024年10月31日止10个月期间的利润表、所有者权益变动表和现金流量表以及相 关财务报表附注。 我们认为，后附的深圳 ...

证券代码：600359 证券简称：新农开发 公告编号：2025—014 单位：万元 项目 计提减值金额 信用减 值损失 应收账款信用减值损失 323.22 其他应收款信用减值损失 -275.44 其他债权投资信用减值损失 -29.40 小计 18.38 资产减 值损失 存货跌价损失 3,863.10 固定资产减值损失 50.47 小计 3913.57 合计 3,895.19 二、本次计提资产减值准备的说明 （一）信用减值损失 资产负债表日，公司以预期信用损失为基础，对应收票据、应收账款和其他 应收款进行减值测试并确认损失准备。经减值测试，本期冲回信用减值损失金额 共计 18.38 万元。 新疆塔里木农业综合开发股份有限公司（以下简称"公司"）于 2025 年 2 月 27 日召开第八届董事会第十九次议和第八届监事会第十七次会议，审议通过 了《关于计提 2024 年资产减值的议案》。现将有关事项公告如下： 一、计提资产减值准备情况概述 为客观、公允地反映公司 2024 年度财务状况和经营成果，基于谨慎性原则， 公司根据《企业会计准则》规定对相关资产进行了减值测试，并对其中存在减值 迹象的资产相应计提了减值准备。 ...

关于上海证券交易所《关于嘉必优生物技术 （武汉）股份有限公司 2022 年业绩快报 更正暨资产减值风险、补充确认关联交易等 有关事项的问询函》回复的核查意见 大信备字[2023]第 2-00012 号 大信会计师事务所（特殊普通合伙） WUYIGE CERTIFIED PUBLIC ACCOUNTANTS LLP. 大信会计师事务所 北京市海淀区知春路 1 号 学院国际大厦 22 层 2206 邮编 100083 WUYIGE Certified Public Accountants LLP. Room2206 22/F,Xueyuan International Tower No.1 ZhichunRoad,Haidian Dist. Beijing,China,100083 电话 Telephone： +86（10）82330558 传真 Fax： +86（10）82327668 网址 Internet： www.daxincpa.com.cn 关于上海证券交易所《关于嘉必优生物技术（武汉）股份有限 公司 2022 年业绩快报更正暨资产减值风险、补充确认关联交 易等有关事项的问询函》回复的核查意见 大信备 ...

江苏精研科技股份有限公司 对江苏精研科技股份有限公司的关注函的回复 头流品的回复 中共华会计师事务所(特殊普通合伙) ZHONGXINGHUA CERTIFIED PUBLIC ACCOUNTANTS LLP 地址: 北京市丰台区丽泽路 20 号丽泽 SOHO Ｂ座 20 层 邮编: 100073 电话:(010) 51423818 传真:(010) 51423816 l 中兴华会计师事务所(特殊普通合伙) ZHONGXINGHUA CERTIFIED PUBLIC ACCOUNTANTS LLP 地址(location):北京市丰台区丽泽路 20 号丽泽 S0H0 B 座 20 层 20/F,Tower B,Lize SOHO,20 Lize Road,Fengtai District,Beijing PR China 电话(tel):010-51423818 传真(fax):010-51423816 中兴华会计师事务所(特殊普通合伙)关于 中兴华报字(2023)第 020009号 深圳证券交易所: 江苏精研科技股份有限公司(以下简称"精研科技"或"公司")于 2023 年 1 月 18 日收到贵所《关于对 ...